Full-year 2015 financial results : Creating the platform for growth

• Cash, cash equivalents and financial instruments amounting to €274 million*;

• Landmark co-development and commercialization agreement with AstraZeneca for monalizumab in immuno-oncology;

• Building foundations for future growth by broadening pipeline and expanding R&D capabilities.

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) reports today its consolidated financial results for the year ended December 31, 2015. The consolidated financial statements are attached to this press release.

Hervé Brailly, Chief Executive Officer and co-founder of Innate Pharma, commented: “2015 was a very important year for Innate Pharma. We signed a landmark co-development and commercialization agreement in April with AstraZeneca which we can leverage on to bring us to the next steps of our corporate progress, i.e. late stage drug development and marketing. The initial payment also gives us financial flexibility which we are using to expand the base of the Company. We are growing the organization, hiring new talent and investing in our proprietary clinical and preclinical pipeline to ensure the future growth of Innate. One tangible move in this direction was the recent acquisition of CD39, a new, preclinical first-in-class checkpoint inhibitor program, and our investment in innovative technologies such as the NK bispecific engagers illustrated by the recently announced collaboration with Sanofi.
As we await important clinical data for lirilumab, we intend to continue to broaden and consolidate our unique positioning in the very promising area of immuno-oncology”.

A conference call will be held today at 2:30pm (CET)
Dial in numbers: +33 (0)1 70 77 09 34

A replay will be available during three months after the conference call.
Dial in number: +33 (0)1 72 00 15 00 - Access number: 298781#

* Including short term investments (€83.0m) and non-current financial instruments (€37.8m)